In Alachua, Florida and Tampa, Florida on December 3, 2025, Axogen, Inc. (NASDAQ: AXGN), a prominent company in the advancement and promotion of cutting-edge surgical technologies for revitalizing peripheral nerve function, revealed that the U.S. Food and Drug Administration (FDA) has given the green light to the Biologics License Application (BLA) for AVANCE® (acellular nerve allograft-arwx).